Overview
The European Commission has approved Sanofi's rabies vaccine, VaxRabeo, for use across all age groups in the European Union, authorizing the vaccine for both pre-exposure and post-exposure prevention of rabies. This marks the first marketing authorization for VaxRabeo and comes after a favorable opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on September 17, 2026.
Vaccine profile and clinical evidence
VaxRabeo is based on Vero-cell technology and was developed with design features intended to lower the risk of allergic reactions. Sanofi says the vaccine demonstrates a longer shelf life compared with its existing rabies products and improved heat stability.
The EU approval was grounded in clinical trials that directly compared VaxRabeo with Sanofi's current rabies vaccines, Verorab and Imovax Rabies. Those studies evaluated the vaccine in both pre-exposure and post-exposure contexts, across all age groups, and applied World Health Organization-recommended vaccination schedules. Results showed VaxRabeo produced comparable protective antibody levels to the existing products and that it delivered high effectiveness when booster doses were administered at either 12 months or in the 24-36 month window after the initial vaccination series.
Shelf life and stability
Sanofi reports that VaxRabeo carries a five-year shelf life and maintains stability at temperatures up to 27°C for 96 hours prior to preparation for use. These attributes are highlighted as improvements relative to the company's current rabies vaccines.
Public health context
According to World Health Organization estimates cited with the approval announcement, rabies remains present in 150 countries and accounts for roughly 59,000 deaths worldwide each year. Transmission is primarily via the saliva of infected animals, most commonly through dog bites. The WHO also indicates that about 29 million people receive post-exposure rabies vaccination annually. The disease is effectively untreatable once clinical symptoms appear, rendering timely vaccination critical because the illness is almost always fatal without it.
Comment from Sanofi
Thomas Triomphe, Head of Vaccines at Sanofi, said: "Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time. This first approval of VaxRabeo is a proud milestone for Sanofi and reflects our commitment to rabies protection, built on five decades of expertise and innovation."
Implications and next steps
The European Commission authorization enables Sanofi to market VaxRabeo across the EU for both pre-exposure and post-exposure rabies prevention in all age groups. The approval is specifically supported by comparative clinical data versus Verorab and Imovax Rabies and by the vaccine's reported stability and shelf-life characteristics.
Note: The article reflects the regulatory decision, clinical findings cited by Sanofi, and the public health statistics referenced in the approval announcement.